2017 American Transplant Congress
Differential Effects of Immunosuppressive Drugs on DNA Methylation in T Cells.
Introduction The immune response after transplantation can be affected by DNA methylation – an epigenetic modification that regulates gene expression, including that of immune-related genes.…2017 American Transplant Congress
Kidney Recipients with 10 Year Belatacept-Treatment Display an Altered T Cell Subset Composition and Low Plasma Cytokine Levels Compared to Matched Patients with CNI-Based Immunosuppression.
Introduction/BackgroundMore than 10 years ago, Belatacept (Bela)-based immunosuppression was investigated in the BENEFIT trial of kidney transplantation (KTx) compared to CNI-based immunosuppression. Bela inhibits T…2017 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients: A Mate Kidney Analysis.
Nephrology, Internal Medicine, Allegheny General Hospital, Pittsburgh, PA
In the current era of powerful maintenance immunosuppression, it is unclear whether induction therapy positively adds to the outcomes in low immune risk kidney transplant…2017 American Transplant Congress
A Pilot Trial of Genotype-Guided Dosing versus Standard Clinical Dosing in Pediatric Solid Organ Transplants.
The Hospital for Sick Children, Toronto, ON, Canada
Purpose: Tacrolimus pharmacokinetics are influenced by age and variation in the CYP3A5 gene with CYP3A5 expressors (AA/AG) being fast metabolizers. The purpose of this trial…2017 American Transplant Congress
Does Blockade of ICOS/ICOS-L Pathway Act Synergistically with αCD40 Costimulation Pathway Blockade?
University of Maryland School of Medicine, Baltimore, MD
Purpose: Inducible costimulator (ICOS) on T cells enhances basic T cell responses to foreign antigen, and increased ICOS expression is detected in association with pathogenic…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
The Efficacy and Safety of Plaquenil in Kidney Transplants Patients with Lupus.
Background: Hydroxychloroquine, also known as Plaquenil ( PLQ) is an antimalarial drug with immunomodulatory action. Recent studies have demonstrated a protective effect of PLQ in…2017 American Transplant Congress
Outcomes and Risk Factors for Graft Loss: Lessons Learned from More Than 1,056 Pediatric Kidney tx at a Single Center.
Aim:To study outcomes and risk factors for graft loss in > 1056 pediatric renal tx.Methods:We studied outcomes by immunosuppression era: I) 1963-83 (ALG, AZA and…2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Oslo, Norway; 2Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…2017 American Transplant Congress
Evolution of Lipid Profile and Major Adverse Cardiac Events in Kidney Transplant Recipients Converted from Calcineurin Inhibitor to Everolimus: 24-Month Subanalysis from Elevate Study.
1ELEVATE Study Group, Berlin, Germany; 2Novartis Pharma AG, Basel, Switzerland
PURPOSE: Posttransplant (post-Tx) lipid abnormalities may increase risk of cardiovascular (CV) events in kidney transplant recipients (KTxR). Previous analysis from ELEVATE (NCT01114529) study confirmed that…
- « Previous Page
- 1
- …
- 97
- 98
- 99
- 100
- 101
- …
- 138
- Next Page »